Haploinsufficiency of Runx2 restores the cranial sutures in a mouse model of Pdgfrb -related craniosynostosis
Human Molecular Genetics · 2025
DOI: 10.1093/hmg/ddaf148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Eri Ogawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan. Hauptthemen laut MEDLINE: Craniosynostoses, Haploinsufficiency, Receptor, Platelet-Derived Growth Factor beta, Core Binding Factor Alpha 1 Subunit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Syndromic forms of craniosynostosis occur as a result of dysregulation of various molecular signaling cascades. In humans, a specific gain-of-function mutation (W566R) in PDGFRB causes a distinctive overgrowth syndrome (OMIM # 616592). Affected individuals exhibit distinctive facial features and craniosynostosis. Using CRISPR/Cas9 gene editing, we generated a mouse model carrying the same pathogenic variant of PDGFRB. The Pdgfrb+/W565R mice exhibited craniosynostosis with skull-base malformation: thus, we successfully recapitulated the human disease phenotype. In humans, haploinsufficiency of RUNX2, a critical transcription factor in osteogenesis, results in defects of the skull and clavicles due to insufficient membranous ossification. Such phenotypes have been well reproduced in Runx2+/− mice. To delineate the molecular mechanisms underlying the development of Pdgfrb-related craniosynostosis, we crossed the Pdgfrb+/W565R mice with Runx2+/− mice. It is noteworthy that the double- mutant mice, i.e. Pdgfrb+/W565R Runx2+/− mice, exhibited near complete restoration of the cranial sutures and skull base. The present observation provides in vivo evidence that overactivation of Pdgfrb signaling leads to craniosynostosis through the effect of Runx2. The phenotypic reversal of the cranial structures suggests that modification of the Pdgfrb-Runx2 signaling cascade might offer a novel therapeutic opportunity for craniosynostosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan.
- Mouse Phenomics Division, RIKEN BioResource Research Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan.
- Experimental Animal Division, RIKEN BioResource Research Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan.
- Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan.
- Department of Neurosurgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.
- Laboratory Animal Resource Center in Transborder Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
ORCID-Profile: Atsushi Yoshiki, Toshiki Takenouchi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ogawa, E., Oikawa, T., Ayabe, S., Miwa, T., Mizuno, S., Nozaki, T., Kosaki, K., Yoshiki, A., Tamura, M., & Takenouchi, T. (2025). Haploinsufficiency of Runx2 restores the cranial sutures in a mouse model of Pdgfrb -related craniosynostosis. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf148
Vancouver
Ogawa E, Oikawa T, Ayabe S, Miwa T, Mizuno S, Nozaki T, et al. Haploinsufficiency of Runx2 restores the cranial sutures in a mouse model of Pdgfrb -related craniosynostosis. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddaf148
BibTeX
@article{Ogawa2025,
author = {Ogawa, Eri and Oikawa, Tomona and Ayabe, Shinya and Miwa, Tomoru and Mizuno, Seiya and Nozaki, Taiki and Kosaki, Kenjiro and Yoshiki, Atsushi and Tamura, Masaru and Takenouchi, Toshiki},
title = {Haploinsufficiency of Runx2 restores the cranial sutures in a mouse model of Pdgfrb -related craniosynostosis},
journal = {Human Molecular Genetics},
year = {2025},
doi = {10.1093/hmg/ddaf148}
}
EUVIMED